Exicure, Inc. (XCUR)
| Market Cap | 71.39M |
| Revenue (ttm) | 500,000 |
| Net Income (ttm) | -9.70M |
| Shares Out | 6.32M |
| EPS (ttm) | -4.75 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 26,602 |
| Open | 9.90 |
| Previous Close | 8.44 |
| Day's Range | 9.90 - 11.05 |
| 52-Week Range | 1.44 - 36.00 |
| Beta | 3.75 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jun 16, 2025 |
About XCUR
Exicure, Inc. does not have significant operations. Previously, the company focused on developing of nucleic acid therapies targeting ribonucleic acid against validated targets. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California. [Read more]
Financial Performance
Financial StatementsNews
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma.
Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML).
Exicure, Inc. Reports Full Year 2024 Financial Results
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Reports Full Year 2024 Financial Results.
Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Issuance of New Patent in Australia.
CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics, Inc.
Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics, Inc.
Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Partners with GPCR Therapeutics Inc. to Fuel New Growth in Biotech.
CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes.
Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes.
Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results.
Exicure, Inc. Receives Extension from Nasdaq Hearings Panel
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today that on September 17, 2024, the Company received notice that the Nasdaq Hearings Panel (“Panel”) gr...
Exicure, Inc. Announces 1-for-5 Reverse Stock Split
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, “the Company”) today announced that it will effect a 1-for-5 reverse stock split of its outstanding shares of common stock (the “Reverse Stock Sp...
Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting.
Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting.
Exicure, Inc. Reports Second Quarter 2024 Financial Results
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Reports Second Quarter 2024 Financial Results.
Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics.
Exicure, Inc. Receives Positive Listing Determination from Nasdaq
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Receives Positive Listing Determination from Nasdaq.
Exicure, Inc. Reports First Quarter 2024 Financial Results
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, the “Company”), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic aci...
Exicure, Inc. Reports Full Year 2023 Financial Results
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Reports Full Year 2023 Financial Results.
Exicure, Inc. Received Nasdaq Notice of a Delisting Determination
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received notice of a delisting determination (the “Staff Delisting Determination”) from the List...
Exicure, Inc. Reports Third Quarter 2023 Financial Results
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against valid...
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (“Nasdaq”) on April 17, 2024 no...
Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis
CHICAGO--(BUSINESS WIRE)--Exicure, Inc., (NASDAQ:XCUR) a company that historically developed nucleic acid therapies, and Bluejay Therapeutics, Inc., a private clinical stage biopharmaceutical company ...
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (“Nasdaq”) on November 22, 2023...
Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. announces appointment of new CEO and CFO and changes to Board of Directors.